IPCA Laboratories Intrinsic Value
IPCA Laboratories (IPCALAB) median intrinsic value is ₹3144.80 from 9 valuation models (range ₹472–₹3931), vs current price ₹1572.40 — +100.0% upside (Trading Below Calculated Value), margin of safety 50.0%. Also explore IPCA Laboratories stock price data download to track price trends across different timeframes.
IPCALAB Valuation Methods Summary — DCF, Graham Number & P/E
IPCA Laboratories intrinsic value across 9 models vs current price ₹1572.40 — upside/downside and value range per method. Browse IPCALAB annual financials for revenue, profit, balance sheet and cash flow data.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹980.32 | ₹784.26 - ₹1176.38 | -37.7% | EPS: ₹44.56, Sector P/E: 22x |
| Book Value Method | asset | ₹3931.00 | ₹3537.90 - ₹4324.10 | +150.0% | Book Value/Share: ₹3355.20, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹3144.80 | ₹2830.32 - ₹3459.28 | +100.0% | Revenue/Share: ₹4134.40, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹3144.80 | ₹2830.32 - ₹3459.28 | +100.0% | EBITDA: ₹2060.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹3931.00 | ₹3144.80 - ₹4717.20 | +150.0% | CF Growth: 4.9%, Discount: 15% |
| PEG Ratio Method | growth | ₹471.72 | ₹424.55 - ₹518.89 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹688.45 | ₹619.61 - ₹757.30 | -56.2% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹3144.80 | ₹2830.32 - ₹3459.28 | +100.0% | ROE: 13.4%, P/E Multiple: 12x |
| Graham Defensive Method | conservative | ₹1834.10 | ₹1650.69 - ₹2017.51 | +16.6% | EPS: ₹44.56, BVPS: ₹3355.20 |
IPCALAB Intrinsic Value vs Market Price — All Valuation Models
IPCA Laboratories fair value range ₹472–₹3931 vs current market price ₹1572.40 across 9 valuation models. For current market price and key ratios, visit IPCA Laboratories share price chart.
IPCALAB Intrinsic Value Analysis — Undervalued or Overvalued?
IPCA Laboratories median intrinsic value ₹3144.80, current price ₹1572.40 — Trading Below Calculated Value by 100.0%, margin of safety 50.0%.
What is the intrinsic value of IPCALAB?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of IPCA Laboratories (IPCALAB) is ₹3144.80 (median value). With the current market price of ₹1572.40, this represents a +100.0% variance from our estimated fair value.
The valuation range spans from ₹471.72 to ₹3931.00, indicating ₹471.72 - ₹3931.00.
Is IPCALAB undervalued or overvalued?
Based on our multi-method analysis, IPCA Laboratories (IPCALAB) appears to be trading below calculated value by approximately 100.0%.
IPCALAB Financial Health — Key Ratios vs Industry Benchmarks
IPCA Laboratories financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 6.05 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 13.4% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | 19.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.88x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
IPCALAB Cash Flow Quality — Operating & Free Cash Flow
IPCA Laboratories operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹1,321 Cr | ₹886 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹945 Cr | ₹338 Cr | Positive Free Cash Flow | 7/10 |
| March 2023 | ₹806 Cr | ₹444 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹856 Cr | ₹431 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹1,090 Cr | ₹830 Cr | Positive Free Cash Flow | 8/10 |